Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Tony J. Hunt is scheduled to present on January 12 at 9:45 a.m. EST. Investors can access a live webcast of the presentation on Repligen’s Investor Relations website, with a replay available for a limited time post-event. Repligen is a leader in developing innovative bioprocessing technologies that enhance the manufacturing of biological drugs, serving biopharmaceutical developers and CDMOs globally.

Repligen Corporation (NASDAQ:RGEN) announced its participation in two investor conferences. The first is Stifel’s 2021 Virtual Healthcare Conference from November 15-17, where CEO Tony J. Hunt will hold a fireside chat on November 17 at 8:00 a.m. EST. The second is the Stephens Annual Investment Conference from December 1-3, featuring CFO Jon K. Snodgres on December 3 at 11:00 a.m. EST. Live webcasts will be accessible through the Investor Relations section of the company’s website, with replays available thereafter.

Repligen Corporation (NASDAQ:RGEN) reported record revenue of $178.2 million for Q3 2021, reflecting an 89% year-over-year growth and 77% organic growth. The company raised its full-year revenue guidance to $655-$665 million. Key highlights include a 49% organic growth from its base business and significant contributions from COVID-related sales, which rose 247%. The gross margin improved to 58.3%, and the fully diluted EPS increased to $0.58. The positive trajectory is attributed to strategic acquisitions and growth in gene therapy revenue.

Repligen Corporation (NASDAQ:RGEN) will release its third quarter 2021 financial results on October 28, 2021, prior to market open. A conference call will follow at 8:30 a.m. EDT to discuss business updates and results for the three- and nine-month periods ending September 30, 2021. Interested parties can access the call by dialing specific numbers based on their location. Repligen, a life sciences company, focuses on innovative bioprocessing technologies for biopharmaceutical manufacturers globally. More details can be found on their website.

Repligen Corporation (NASDAQ:RGEN) has entered into a definitive agreement to acquire Avitide Inc. for approximately $150 million. The deal includes $75 million in cash and $75 million in Repligen common stock, alongside performance-based earnouts over three years. This acquisition aims to enhance Repligen’s Proteins business, particularly in affinity ligand solutions for gene therapy, with Avitide expected to contribute about $10 million in revenue in 2022 and positively impact adjusted earnings per share in 2023.

Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH announced the successful development of a novel protein A ligand called NGL-Impact A Hi pH. This innovative ligand addresses critical challenges in purifying pH sensitive antibodies and Fc-fusion proteins, notably reducing antibody aggregation during purification. Customer evaluations showcased a two-fold decrease in aggregate formation while maintaining high dynamic binding capacity. The ligand is set for commercialization via a new resin later this year, potentially offering significant cost and time savings for developers in the biopharmaceutical industry.

Repligen Corporation (NASDAQ:RGEN) reported Q2 2021 revenue of $163.0 million, achieving an 86% year-over-year growth and 69% organic growth. The company raised its revenue guidance for 2021 to $625-$645 million from previous estimates of $565-$590 million. The acquisition of Polymem S.A. further enhances Repligen's capabilities. Key financial metrics include a GAAP EPS of $0.64 and adjusted EPS of $0.79 for the quarter. The company anticipates a gross margin of 59%-60% for the year, reflecting ongoing strong performance.

Repligen Corporation (NASDAQ:RGEN) will report its Q2 2021 financial results on July 27, 2021. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. EDT to discuss financial results for the three- and six-month periods ending June 30, 2021. Domestic callers can dial (844) 274-3999, while international callers can use (412) 317-5607. The call will also be available via a webcast on the company’s Investor Relations webpage, with archived access provided as well.